Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price fell 14.5% during mid-day trading on Monday . The company traded as low as C$0.27 and last traded at C$0.27. 438,482 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Performance
The company has a market cap of C$23.96 million, a PE ratio of -13.75 and a beta of 0.20. The firm has a fifty day simple moving average of C$0.11 and a 200 day simple moving average of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Stock Market Upgrades: What Are They?
- Super Micro Computer: Turning Risk Into Reward at the Crossroads
- Following Congress Stock Trades
- After a Reset Year, Is Moderna Stock Poised for a Comeback?
- What is Forex and How Does it Work?
- Retail Trends Spark Analyst Upgrades for DICK’s Sporting Goods
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
